Nav: Home

Pitt cancer researchers honored with 2017 Paul Ehrlich and Ludwig Darmstaedter Prize

January 25, 2017

PITTSBURGH -- One of the most prestigious awards in the field of medicine will be presented to University of Pittsburgh School of Medicine faculty members Yuan Chang and Patrick S. Moore.

The duo, whose Chang-Moore Laboratory is credited with discovering two of the seven known human viruses that directly cause cancer, will receive the 2017 Paul Ehrlich and Ludwig Darmstaedter Prize. The award is given annually to medical researchers who have made significant contributions in the fields of immunology, cancer research, microbiology, and chemotherapy.

"Drs. Chang and Moore's contributions to cancer research have been significant and lasting, touching the lives of people around the world," said Arthur S. Levine, Pitt's senior vice chancellor for the health sciences and the John and Gertrude Petersen Dean of the School of Medicine. "They are the first Pitt faculty members to ever be honored with the Paul Ehrlich and Ludwig Darmstaedter Prize. The University community congratulates them and celebrates this well-deserved tribute to the pioneering work that has come to define their careers."

Chang and Moore discovered the Kaposi's sarcoma-associated herpes virus, or human herpesvirus 8 (KSHV/HHV8) in 1994. The virus causes Kaposi's sarcoma, the most common AIDS-related malignancy and one of the most frequently occurring cancers in Africa. Prior to this discovery, medical researchers had worked for nearly 15 years to find an infectious agent associated with Kaposi's sarcoma. The pair also identified Merkel cell polyomavirus (MCV)--the cause of Merkel cell carcinoma, one of the world's most clinically aggressive skin cancers--in 2008.

The two have been widely recognized for their work, which has garnered some of the highest national and international honors in medicine, infectious disease, and cancer. Together they have been honored with the 2012 Marjorie Stephenson Prize from the Society of General Microbiology in the United Kingdom, the 2003 Charles S. Mott Award from the General Motors Cancer Research Foundation, the 1998 Robert Koch Prize, and the 1997 Meyenburg Prize. Chang and Moore are also elected fellows of the National Academy of Sciences.

Chang's current research centers on viral oncogenesis with efforts specifically focused on KSHV, MCV, and new pathogen discovery. Moore's research focuses on addressing cancers caused by viruses and how this information can be used to understand molecular causes for noninfectious cancers.

The award honoring Chang's and Moore's work is named for renowned German scientists Paul Ehrlich and Ludwig Darmstaedter. The prize is given by the Paul Ehrlich Foundation, which is managed by the Association of Friends and Sponsors of the Goethe University in Frankfurt, Germany. The foundation presents the honor annually in Frankfurt on Ehrlich's birthday, March 14.

Yuan Chang:

A pathologist and virologist, Yuan Chang is an American Cancer Society Research Professor and a Distinguished Professor of Pathology in the University of Pittsburgh School of Medicine.

Chang has been a faculty member in Pitt's School of Medicine since 2002. Prior to joining Pitt, she held faculty positions in Columbia University's College of Physicians and Surgery and at Stanford University Medical Center. Chang also served as a research scientist at the DNAX Research Institute of Molecular Biology in Palo Alto, Calif.

In 2015, then-president Barack Obama appointed Chang to serve on the United States' National Cancer Advisory Board, which advises the National Institutes of Health on promising cancer research. Her other notable honors include elections to the American Society for Clinical Investigation, the American Academy of Microbiology, and the Association of American Physicians. Chang was a past recipient of the 2010 Howard Taylor Ricketts Award from the University of Chicago and the 2003 Paul Marks Prize for Cancer Research from the Memorial Sloan Kettering Cancer Center.

Chang earned a Bachelor of Science degree in biology at Stanford University in 1981 as well as her Doctor of Medicine degree at the University of Utah's College of Medicine in 1987.

Patrick S. Moore:

An epidemiologist and virologist, Patrick S. Moore is the director of the Cancer Virology Program at the University of Pittsburgh Cancer Institute. He is an American Cancer Society Research Professor, a Distinguished Professor of Microbiology and Molecular Genetics, and the Pittsburgh Foundation Chair in Innovative Cancer Research in the University of Pittsburgh School of Medicine.

Last year, the National Cancer Institute recognized Moore's contributions to medical research with its Outstanding Investigator Award.

Before coming to Pitt in 2002, Moore was a faculty member in the Division of Epidemiology at Columbia University's Mailman School of Public Health. He also has served as the deputy commissioner of the New York City Department of Health and the chief of the Epidemiology Section of the Arboviral Diseases Branch at the Centers for Disease Control in Fort Collins, Colo.

Moore earned a Bachelor of Science in biology at Westminster College, a master's degree in chemistry at Stanford University, a Doctor of Medicine degree at the University of Utah, and a Master of Public Health degree at the University of California, Berkeley.

University of Pittsburgh

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...